TITLE

Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV-1 Vaccine among Injection Drug Users in Bangkok, Thailand

AUTHOR(S)
Pitisuttithum, Punnee; Gilbert, Peter; Gurwith, Marc; Heyward, William; Martin, Michael; van Griensven, Fritz; Hu, Dale; Tappero, Jordan W.; Choopanya, Kachit
PUB. DATE
December 2006
SOURCE
Journal of Infectious Diseases;12/15/2006, Vol. 194 Issue 12, p1661
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. In Thailand, phase 1/2 trials of monovalent subtype B and bivalent subtype B/E (CRF01_AE) recombinant glycoprotein 120 human immunodeficiency virus type 1 (HIV-1) vaccines were successfully conducted from 1995 to 1998, prompting the first HIV-1 vaccine efficacy trial in Asia. Methods. This randomized, double-blind, placebo-controlled efficacy trial of AIDSVAX B/E (VaxGen), which included 36-months of follow-up, was conducted among injection drug users (IDUs) in Bangkok, Thailand. The primary end point was HIV-1 infection; secondary end points included plasma HIV-1 load, CD4 cell count, onset of acquired immunodeficiency syndrome-defining conditions, and initiation of antiretroviral therapy. Results. A total of 2546 IDUs were enrolled between March 1999 and August 2000; the median age was 26 years, and 93.4% were men. The overall HIV-1 incidence was 3.4 infections/100 person-years (95% confidence interval [CI], 3.0–3.9 infections/100 person-years), and the cumulative incidence was 8.4%. There were no differences between the vaccine and placebo arms. HIV-1 subtype E (83 vaccine and 81 placebo recipients) accounted for 77% of infections. Vaccine efficacy was estimated at 0.1% (95% CI, -30.8% to 23.8%; P = .99, log-rank test). No statistically significant effects of the vaccine on secondary end points were observed. Conclusion. Despite the successful completion of this efficacy trial, the vaccine did not prevent HIV-1 infection or delay HIV-1 disease progression.
ACCESSION #
23138236

 

Related Articles

  • Old vaccine trial draws new scrutiny. McEnery, Regina // VAX; 

    The article offers information related to premature termination of a Phase IIb Human Immunodeficiency Virus (HIV) vaccine trial in the U.S. known as HVTN 505, which has led to the fresh analysis of termination of a Phase IIb study from South Africa which was halted a few months after it started...

  • Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India. Mehendale, Sanjay; Sahay, Seema; Thakar, Madhuri; Sahasrabuddhe, Sushant; Kakade, Meghana; Shete, Ashwini; Shrotri, Aparna; Spentzou, Aggeliki; Tarragona, Tony; Stevens, Gwynneth; Kochhar, Sonali; Excler, John Louis; Fast, Pat; Paranjape, Ramesh // Indian Journal of Medical Research;Aug2010, Vol. 132 Issue 2, p168 

    Background & objective: A phase 1 trial of adeno-associated virus based HIV-1 subtype C vaccine (tgAAC09) was conducted at two sites in Germany and Belgium and one site in India. This paper reports the safety and immunogenicity of tgAAC09 in healthy adult Indian volunteers. Methods: Between...

  • High-Dose Recombinant Canarypox Vaccine Expressing HIV-1 Protein, in Seronegative Human Subjects. Goepfert, Paul A.; Horton, Helen; McElrath, M. Juliana; Gurunathan, Sanjay; Ferrari, Guido; Tomaras, Georgia D.; Montefiori, David C.; Allen, Mary; Ya-Lin Chiu; Spearman, Paul; Fuchs, Jonathan D.; Koblin, Beryl A.; Blattner, William A.; Frey, Sharon; Keefer, Michael C.; Baden, Lindsey R.; Corey, Lawrence // Journal of Infectious Diseases;10/1/2005, Vol. 192 Issue 7, p1249 

    Background. In clinical trials, canarypox ALVAC-human immunodeficiency virus (HIV) vaccines have been shown to elicit human HIV-specific cytotoxic T lymphocyte (CTL) responses in some but not all healthy uninfected adults. Methods. A clinical trial was conducted to examine whether the vaccine...

  • HIV-1 Virologic and Immunologic Progression and Initiation of Antiretroviral Therapy among HIV-1--Infected Subjects in a Trial of the Efficacy of Recombinant Glycoprotein 120 Vaccine. Gilbert, Peter B.; Ackers, Marta L.; Berman, Phillip W.; Francis, Donald P.; Popovic, Vladimir; Hu, Dale J.; Heyward, William L.; Sinarigil, Faruk; Shepherd, Bryan E.; Gurwith, Marc // Journal of Infectious Diseases;9/15/2005, Vol. 192 Issue 6, p974 

    The first trial of the efficacy of a human immunodeficiency virus (HIV)-1 vaccine was conducted in North America and The Netherlands between 1998 and 2003. This multicenter, randomized, placebo-controlled trial of a recombinant glycoprotein 120 vaccine included 5403 initially HIV-negative...

  • Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial. Zolla-Pazner, Susan; deCamp, Allan C.; Cardozo, Timothy; Karasavvas, Nicos; Gottardo, Raphael; Williams, Constance; Morris, Daryl E.; Tomaras, Georgia; Rao, Mangala; Billings, Erik; Berman, Phillip; Xiaoying Shen; Andrews, Charla; O'Connell, Robert J.; Ngauy, Viseth; Nitayaphan, Sorachai; Souza, Markde; Korber, Bette; Koup, Richard; Bailer, Robert T. // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox (ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously shown to have a 31.2% efficacy rate. Plasma specimens from vaccine and placebo recipients were used in an extensive set of assays to...

  • Merck HIV Vaccine Ineffective in Clinical Trial.  // Travel Medicine Advisor;Nov2007, Vol. 17 Issue 11, p2 

    The article reports on the ineffectiveness of HIV vaccine from Merck in a large clinical trial that made the company halt further test vaccinations. A trial which was started in 2004 has identified 24 new HIV infections in the group who received the vaccine compared to 21 infections in the...

  • Placebo-Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV-1 Infection.  // Journal of Infectious Diseases;3/1/2005, Vol. 191 Issue 5, p654 

    The article reports a clinical trial related to a vaccine needed to prevent human immunodeficiency virus type 1 (HIV-1) infection. A double-blind, randomized trial of a recombinant HIV-1 envelope glycoprotein subunit (rgp120) vaccine was conducted among men who have sex with men and among women...

  • Phase I Randomised Clinical Trial of an HIV-1CN54, Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally. Lewis, David J.; Fraser, Carol A.; Mahmoud, Abdel N.; Wiggins, Rebecca C.; Woodrow, Maria; Cope, Alethea; Chun Cai; Giemza, Rafaela; Jeffs, Simon A.; Manoussaka, Maria; Cole, Tom; Cranage, Martin P.; Shattock, Robin J.; Lacey, Charles J. // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    We conducted a phase 1 double-blind randomised controlled trial (RCT) of a HIV-1 envelope protein (CN54 gp140) candidate vaccine delivered vaginally to assess immunogenicity and safety. It was hypothesised that repeated delivery of gp140 may facilitate antigen uptake and presentation at this...

  • HIV vaccine reduces infection rate by a third, randomised trial of 16 400 shows. Mayor, Susan // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/3/2009, Vol. 339 Issue 7724, p772 

    The article reports on the results of a study released by the U.S. Military HIV Research Program which evaluated the efficacy of an experimental vaccine in preventing HIV infection aside from its ability to reduce the amount of HIV in the blood of those who became infected after vaccination. The...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics